Gareth Wayne
GlaxoSmithKline (United Kingdom)(GB)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Alzheimer's disease research and treatments, Cholinesterase and Neurodegenerative Diseases, Monoclonal and Polyclonal Antibodies Research, Protease and Inhibitor Mechanisms
Most-Cited Works
- → Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo(2006)198 cited
- → Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's β-secretase(2003)179 cited
- → Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery(2017)90 cited
- → Direct Measurement of Intracellular Compound Concentration by RapidFire Mass Spectrometry Offers Insights into Cell Permeability(2015)68 cited
- → TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4(2007)65 cited
- → Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability(2008)65 cited
- → BACE-1 inhibitors part 3: Identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells(2008)57 cited
- → BACE-1 inhibitors part 2: Identification of hydroxy ethylamines (HEAs) with reduced peptidic character(2008)56 cited
- → Recent advances in human respiratory epithelium models for drug discovery(2021)54 cited
- → Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics(2009)54 cited